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Abstract
Most cervical cancer (CxCa) are related to persistent infection with high-risk human papillomavirus (HR-HPV) in the cervical 
mucosa, suggesting that an induction of mucosal cell-mediated immunity against HR-HPV oncoproteins can be a promising 
strategy to fight HPV-associated CxCa. From this perspective, many pre-clinical and clinical trials have proved the potential 
of lactic acid bacteria (LAB) genetically modified to deliver recombinant antigens to induce mucosal, humoral and cellular 
immunity in the host. Altogether, the outcomes of these studies suggest that there are several key factors to consider that 
may offer guidance on improvement protein yield and improving immune response. Overall, these findings showed that 
oral LAB-based mucosal HPV vaccines expressing inducible surface-anchored antigens display a higher potential to induce 
particularly specific systemic and mucosal cytotoxic cellular immune responses. In this review, we describe all LAB-based 
HPV vaccine investigations by reviewing databases from international studies between 2000 and 2020. Our aim is to promote 
the therapeutic HPV vaccines knowledge and to complete the gaps in this field to empower scientists worldwide to make 
proper decisions regarding the best strategies for the development of therapeutic HPV vaccines.
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Introduction
Cervical cancer (CxCa) is considered the 4th most com-
mon cancer in women after breast, colorectal and lung [1]. 
Development of CxCa is closely associated with persistent 
genital infection with high risk human papillomavirus 
(HR-HPV) [2]. According to previous publications, HPV 
type 16 (HPV-16) is considered as the main widespread 
genotype associated with development of invasive CxCa [3, 
4]. High prevalence of HPV infection, genital warts, and 
CxCa has encouraged researchers to pursue experimental 
lines of investigation for the development and widespread 
delivery of safe and effective prophylactic HPV vaccines 
to control HPV infection [5]. Most prophylactic vaccines 
to prevent HPV infections are based on virus-like particle 
(VLP) derived from HPV L1 capsid proteins. Although HPV 
vaccines are now used worldwide to block HPV infection, 
they are not efficient to treat (i.e., a therapeutic effect) per-
sistent infections in millions of patients, who have already 
been infected with HPV [6, 7]. Thus, scientific communities 
focus on developing therapeutic HPV vaccines which can 
stimulate robust immunogenicity against HPV oncoproteins. 
Indeed, it has been demonstrated that high-risk E6 and E7 
oncoproteins are constitutively expressed in CxCa and thus 
they represent reliable candidates for the development of 
therapeutic vaccines against HPV-associated CxCa [8]. So 
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far, different types of HPV therapeutic vaccines have been 
developed, including vaccines based on: live vectors, pro-
teins, peptides, DNA and whole cell-based vaccines. Most 
of these therapeutic vaccines can induce systemic immune 
response through delivery of E6/E7 oncogenes via intramus-
cular or subcutaneous routes, which need trained personnel 
and suffer several limitations [9]. Recently, several studies 
have focused on development of innovative, safe, mucosally 
administered vaccines to avoid the adverse effects of sys-
temic immunization routes.
The genital mucosa is the main and specific site for the 
entry of HPV-16 virus as well as its infection. The vagina 
hosts a complex microbial community (dominated by Lac-
tobacillus spp.) that plays crucial roles in maintaining health 
and homeostasis. In addition, it has long been known that 
gut microbiota could affect the local immune system and 
diseases. As such, the concept of gut-vagina axis postulates 
that modulations of gut microbiota composition may have a 
profound effect on course of disease in patients with genital 
disease through flow of immune signals from the gut to the 
vagina. Extensive literature has attempted to correlate the 
gut microbiota and immune system such as its effect on local 
health homeostasis. Also, the long-reaching immune effect 
of gut microbiota on vaginal diseases is now being well 
documented [10]. Despite this, the gut–vagina axis remains 
less studied than the gut–brain and gut–lung axis. Moreover, 
little has been achieved in the successful prevention or treat-
ment of vaginal disease by modulation of gut microbiota, 
especially mucosal immunization (Fig. 1). Some studies sug-
gest that mucosal vaccines can be more effective and valu-
able than systemic ones due to their unique properties such 
as greater convenience and lower costs [11]. Furthermore, 
these vaccines are easier to administrate (self-administra-
tion) and less invasive than systemic vaccines, where the 
use of a needle is always necessary and of trained personnel 
for administration. Mucosal vaccines also represent a more 
attractive and simpler way to implement in vaccination cam-
paigns (i.e., public health priority), especially when applied 
to children and immunosuppressed patients [12].
To the best of our knowledge, one of the most effective 
strategies to deliver vaccine antigens to mucosal surfaces for 
an optimal immunization is the use of bacterial vaccines. In 
the last years, several studies have suggested that the strategy 
to deliver vaccine antigens for immunization via live-attenu-
ated bacterial pathogens is not safe and can represent risks, 
especially in children, elder, and immunosuppressed patients 
[13]. Thus, evidence is mounting that there is an urgent need 
for developing more advanced, safe, and efficient mucosal 
Fig. 1  Induction of specific mucosal immunity via oral administra-
tion of LAB-based vaccine. Since all mucosal sites share a common 
immune response via specific mucosal lymphocytes, it is proposed 
that oral immunization with recombinants L. lactis and L. casei har-
boring HPV oncoprotein have the ability to provoke strong mucosal 
immune responses in the gut and in the cervix. It may be due to the 
interaction between gut with vagina (gut–vagina axis), with positive 
consequences on vaginal health and treatment of CxCa
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antigen-delivery vehicles. Over the last two decades, enough 
data has been generated confirming the interest in the use 
of Gram-positive, non-pathogenic, and non-invasive lactic 
acid bacteria (LAB) genetically modified to produce and 
deliver prophylactic and therapeutic antigens to mucosal 
surfaces (Fig. 2) [14–17]. LAB, such as Lactobacillus and 
Lactococcus spp., have gained considerable attention for 
large-scale production of heterologous proteins because of 
their particular interesting features. Based on these findings, 
many scientists around the world have tried to design a new 
generation of mucosal live vaccines [18–20]. As we will dis-
cuss in the next sections, an increasing body of both in vivo 
and clinical trial evidences seem to highlight the role of this 
new generation of mucosal live vaccines on inducing both 
local and systemic immune responses involved in HPV. This 
support the hypothesis of a close interplay between mucosal 
delivery of HPV antigens by LAB and host mucosal as well 
as humoral and/or cellular immune systems involved in in 
the effective elimination of foreign invaders. Regardless of 
immunity, it is now understood that safety, intrinsic adju-
vant properties, less laborious, inexpensive to produce, and 
more easily usable of LAB-based vaccine play a significant 
beneficial role during mucosal vaccination. Nevertheless, 
the precise mechanisms related to LAB-based vaccines and 
HPV, in particular in CxCa patients, are still debated and dif-
ficult to ascertain due to some limitations such as low num-
ber of study participants during clinical trials and lack of 
knowledge of the next phase results of clinical trials. Also, 
at the very least it needs to be stressed that induction in one 
mucosal site generally induces a much greater response at 
that site than in distal mucosal sites. Sorting this out would 
enhance our understanding of the role of new generation 
of mucosal live vaccine in the context of HPV and CxCa. 
Thus, many authors have also been encouraged to investigate 
the new generation of mucosal live vaccine in battle against 
HPV.
Up to date, several mucosal vaccines based on geneti-
cally modified LAB against HPV-16 L1, L2, E2, E6, and 
E7 antigens have been developed (Tables 1 and 2). Most 
important, preclinical as well as clinical trials phases I and 
II (Table 3) have been completed to evaluate the ability of 
these recombinant LAB in stimulating an immune response 
(we will summarize their roles and the obtained results later 
in this review). Until now, no review has addressed and com-
pared HPV vaccines based on the use of genetically modi-
fied LAB. To gain insight from global efforts, we decided 
Fig. 2  Schematic representation of the method commonly used to develop HPV vaccines based on LAB and determination of vaccine efficacy as 
well as safety in mice models as well as human subjects through pre-clinical and clinical trial studies
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to perform a complete review of the relevant literature and 
randomized controlled trials to provide a meticulous sum-
mary in the field of the development and the use of mucosal 
vaccines based on LAB to treat HPV. We also provide a 
comparison about their advantages and/or drawbacks and 
their potential role in inducing an HPV-specific immune 
response. Our aim is to address the following questions: (i) 
which type of immunity can be induced after administration 
of either prophylactic or therapeutic LAB-based vaccines 
against HPV? (ii) how can we elucidate the link between 
LAB-based vaccines, mucosal immunity and gut-vagina 
axis? (iii) which factors can determine the effectiveness of 
LAB-based HPV vaccines? (iv) how we can improve the 
efficiency of LAB-based HPV vaccines to enhance their 
efficiency against CxCa? (v) is prescription of LAB-based 
HPV vaccines safe for humans? (vi) have LAB-based HPV 
vaccines studies reached clinical trial phases and what is 
the latest situation of clinical studies? We hope that this 
review will offers a look at important aspects regarding the 
future HPV vaccines and in scheduling future studies on 
HPV infections.
Prophylactic LAB‑based HPV vaccines can 
efficiently produce VLPs intracellularly 
with conformational epitopes
Over multiple consecutive years, different strategies have 
been tested for developing prophylactic HPV vaccines. 
Many studies have reported that HPV-16 L1 genes are 
promising candidates for the production of prophylactic 
HPV vaccines. Several HPV VLP-based prophylactic vac-
cines have been licensed by the FDA, commercialized, and 
are currently available in the market, which can stimulate 
long-term protective immune responses through producing 
type-specific neutralizing antibodies [21–23]. A compari-
son between the expression of a desired antigens in tradi-
tional expression systems versus LAB for designing mucosal 
vaccine delivery systems, suggests that these last are more 
suitable, safe, and cheapest [24]. In this context, the results 
of some studies have emphasized that oral immunization 
in mice receiving L. lactis harboring HPV-16 L1 antigens 
could induce significant levels of mucosal IgA antibodies; 
however, virus-neutralizing activity to evaluate the quality of 
stimulated antigen-specific antibodies was not evaluated in 
this study [25]. On the other hand, several studies found that 
production of HPV-16 L1 in some prokaryotic expression 
systems result in insoluble inclusion bodies necessitating the 
in vitro refolding protocols for the production of VLPs [26]. 
Meanwhile, scientists proved the hypothesis that recombi-
nant LAB, such as Lactobacillus, can open a new window 
for expression of L1-based VLPs as well as for develop-
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VLP production, for the first time, Aires et al. confirmed that 
Lactobacillus casei could produce recombinant L1 protein 
which can self-assemble into intracellular VLPs. They also 
injected subcutaneously the above-mentioned vaccine in 
mice and found that the obtained sera can react with insect 
cell-expressed VLPs. They suggested that the L1 protein 
may adopt a native conformation when produced by L. casei 
[27]. Nevertheless, more studies are necessary to completely 
prove this hypothesis. Similarly, Cortes-Perez et al. observed 
that L. lactis could produce recombinant L1 protein which 
can self-assemble into morphological structures similar to 
intracellular VLPs, indicating preservation of conforma-
tional epitopes. Indeed, the data obtained from research stud-
ies proposed that the production of a mixture of intracellular 
and extracellular forms of HPV-16 L1 protein by L. lactis is 
more operative for stimulation of both systemic and mucosal 
immune responses. Although they found the stimulation of 
IgG-specific antibodies following L. lactis-based HPV16 L1 
production but they did not compare the levels of induced 
antibodies with those induced by IM VLP injection and did 
not evaluate the efficacy of these recombinant strains in vivo 
in mice [28]. In addition to L1 protein, N-terminal region 
of L2 minor capsid protein of HPV-16 also has immune-
stimulating properties, where L2-specific antibodies can 
show cross-neutralizing activity against different types of 
HPV, thereby introducing themselves as a potential target 
for developing a prophylactic vaccine [29]. In line with the 
findings of Yoon et al., it was found that oral immuniza-
tion with L. casei carrying an anchored form of HPV-16 L2 
protein can stimulate L2-specific serum IgG and mucosal 
IgA antibodies. Altogether, these outcomes recommend the 
feasibility in the use of LAB as a delivery vector of HPV-16 
L1 and L2 to develop new HPV-vaccines [30].
Preclinical studies on therapeutic LAB‑based 
HPV vaccines confirm that the induced 
mucosal immunity as well as systematic 
immunity display antitumor effects on HPV 
E6/E7‑associated neoplastic lesions
Because of the lack of virion capsid proteins in CxCa 
patients, to date, prophylactic vaccines have been only pre-
scribed for prophylactic purposes, since they are not effec-
tive to treat persistent HPV infection. Therefore, there is a 
real need to develop therapeutic HPV vaccines to treat pre-
existing HPV infections to decrease the incidence of CxCa. 
Different murine models have been used in several studies 
on HPV therapeutic vaccines such as Bermúdez-Humarán 
et al., who described that intranasal immunization with a 
LAB expressing HPV-16 E7 antigen and IL-12 cytokine 
can induce antitumor effects on E7-related tumors. In light 
of these findings, the authors claimed the prevention of 
TC-1-induced tumors after immunization with above-men-
tioned vaccine especially after a second vaccination. This 
positive feedback model seems to be supported by the fact 
that long-lasting immunity is estimable. In addition, their 
therapeutic experiments determined antitumor effects of 
the vaccination through a CTL response. This study raises 
questions about E7-specific mucosal immune response and 
whether it has greater potential to elicit immune response 
against HPV-related CxCa [31]. However, this information 
is not highly predictive of mucosal immunity, providing an 
incomplete picture of antigen specificity of mucosal lym-
phocytes and mucosal cellular immune responses in the gas-
trointestinal tract and the cervix after immunization with a 
LAB-based vaccine.
To accurately assess the impact of mucosal vaccine dur-
ing HPV infection, cell-mediated immune responses and a 
therapeutic vaccine which are able to induce a cell-mediated 
immunity (CMI) against HPV-16 E6 and/or E7 oncoproteins 
are critical. All mucosal sites are composed of collaborative 
immune networks that include induction of specific mucosal 
lymphocytes. The mucosal lymphocytes appeared to be a 
combination of T cells from GALT (Gut-associated lym-
phoid tissue), lamina propria, and intraepithelial compart-
ments. The integrin α4β7 is a mucosa-associated homing 
receptor within wide ranges of the lymphocyte and whose 
expression is usually induced by dendritic cells (DCs) resid-
ing in the GALT [32, 33]. It has also a key role in proficient 
trafficking and preservation of lymphocytes in mucosal sites 
such as nasal, urogenital, and other areas [34]. According to 
these important points mentioned above, to generate strong 
mucosal immune responses in the gastrointestinal tract and 
the cervix, oral vaccination with recombinant LAB must 
promptly induce GALT and integrin α4β7+ memory/effector 
cells. Hence, mucosal lymphocytes gained from the intes-
tinal mucosa have been used for assessing cellular immune 
response in several research studies. In accordance with the 
above fact, Adachi et al. highlighted that oral consumption 
of L. casei with HPV-16 E7 antigen produced E7-specific 
IFN-γ-producing cells and provoked GALT and integrin 
α4β7+ memory/effector cells, leading to enhanced mucosal 
immunity in gut-derived integrin α4β7+ lymphocyte. How-
ever, in this study the authors isolated mucosal T cells from 
gut mucosa instead of the cervix because of the difficulty 
to obtain these last cells. In this case, identical homing of 
primed memory/effector cells from the gut inductive site to 
effector sites in the cervical mucosa may cooperate for elim-
ination of high-grade CIN [32]. Similarly, Mohseni et al. 
and Taghinezhad-S et al. found that oral immunization with 
recombinant L. lactis producing HPV-16 E6/E7 oncopro-
teins enhanced mucosal cellular immunity such as E6- and 
E7-specific IL-2- and IFN-γ-positive  CD4+ and CD8 + T 
cell numbers in antigen-stimulated splenocytes, intestinal 
mucosal lymphocytes, and vaginal lymphocytes, suggesting 
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that mucosal lymphocyte population include memory T cells 
which recognize E6/E7 antigens. Most important, their 
recombinant L. lactis strains induced significantly higher 
levels of immune response to MHCII (E6/7-specific  CD4+ 
T helper) and MHCI (E6/7-specific  CD8+ T cell) epitopes 
from recombinant E6/E7 [20, 35]. These outcomes support 
the results of Lee et al., who observed that oral administra-
tion of L. casei harboring PgsA-E6 oncoprotein contributes 
to stimulation of E6-specific T cell responses in mesenteric 
lymph nodes (MLN), splenocytes, and vaginal samples [36].
These new advances in the field of therapeutic vaccine 
research to treat HPV can lead to a rapid progress and effec-
tiveness in clinical responses via stimulation of mucosal 
E6/E7-specific CTL response. In this context, diminished 
growth of subcutaneous TC-1 tumoral cells and induction 
of E7-specific type1 immune response-correlated splenic 
T cells were reported by Korean scientists. They demon-
strated that oral immunization of mice with L. casei-PgsA-
E6/E7 can reduce the tumor size and improve survival rate 
[37]. This was further supported by recent in vivo studies, 
where vaccination of mice challenged with a lethal dose of 
the tumor cell line TC-1 with recombinant L. lactis were 
associated with an effective antitumor protection against an 
E6- and E7-expressing tumor cells (i.e., TC-1) and a higher 
survival rate compared to control animals. Additionally, 
the outcomes showed robust therapeutic anti-cancer effects 
against recognized tumors in vivo [20, 35]. Similarity, Li 
et al. showed that intranasal immunization of mice with 
live L. lactis containing HPV-16 E7 oncoprotein can elicit 
a E7-specific protective and therapeutic immune response 
against TC-1 tumors [38]. In all of the abovementioned 
reports, researchers found that antigen-specific serum anti-
body and mucosal immune responses can only be induced 
after prime-boost immunizations. Since an important amount 
of the administered L. lactis may migrate from the gut into 
the colon and remain there for a short time before go out in 
the feces, there is little chance that a single vaccination can 
elicit substantial amounts of antigen-specific antibodies. For 
this reason, the stimulation of antigen-specific antibodies 
has been seen in numerous studies after at least 2 or 3 times 
of multiple vaccinations [25, 39]. Overall, these preclinical 
findings suggest the possibility of the cheap mucosal immu-
nization approaches against HPV-linked CxCa.
Clinical trial studies of HPV vaccine based 
on LAB
Currently, conization is the only option for the treatment 
of stage III carcinoma of the cervix associated to HPV. 
However, this procedure may cause some adverse effects 
especially in pregnant women such as miscarriage, pre-
mature birth, and recurrence of cancer. This encourages 
researchers to develop an effective medicine for treatment 
of CxCa. Former clinical trials in humans have revealed 
that their vaccine construct can provoke HPV-specific 
humoral and cytotoxic T-cell response [40–43]. On the 
other hand, due to the therapeutic potential of HPV onco-
genes in high-grade cervical intraepithelial neoplasia, 
many studies have sought to understand which therapeu-
tic approaches can lead to an improvement in the fre-
quency of lesion eradication. Thus, some researchers have 
hypothesized that injectable vaccines are involved in the 
induction of specific immune responses against HPV and 
regression of cervical intraepithelial neoplastic lesions. 
Regarding this concept, the Santin group was interested in 
elucidating the effect of the full-length E7-pulsed autolo-
gous dendritic cells (DC) in autologous tumor target cells. 
Consistent with this idea, they documented the effect of 
their vaccine on expression of E7-specific  CD8+ cytotoxic 
T-lymphocyte (CTL) in three CxCa patients challenged 
with HPV-16 and 18 along with E7-specific  CD4+ T-cell 
proliferative responses against HPV-infected cancer cells. 
This work had motivated clinical studies that had revealed 
the role of therapeutic HPV vaccine strategy in produc-
tion of antigen-specific immunity and for the treatment of 
CxCa patients [44]. Shortly thereafter, this concept was 
reinforced by the observation that synthetic peptide vac-
cines composed of 9-amino acid from HPV-16 E7 and/or 
protein encoding a bacterial heat shock protein fused to 
HPV-16 E7 sequences could stimulate E7-specific immune 
response, eliminate intraepithelial neoplasia, and clear 
the HPV from cervical scrapings in women with CxCa; 
however, low efficacy of the aforementioned vaccines was 
reported in those patients [45, 46]. Sheets et al., in a phase 
I proof-of-concept clinical trial displayed the production 
of HPV-specific T-cell responses and development of IgA 
anti-E2–specific antibody in women vaccinated with bac-
terial plasmid harboring a 13 amino acid from HPV E7 
gene which was surrounded by microparticles, without 
any serious adverse events. The study had a considerable 
limitation: regardless of safety, their data exhibited low 
immunogenicity in vaccinated women [42]. Overarching 
results gathered from these series of studies provide an 
additional link between how therapeutic HPV vaccine can 
ultimately contribute to the inhibition of cervical cancer. 
Nevertheless, the main drawbacks of these approaches are 
long-time complete response and negligible effects on cer-
vical intraepithelial neoplastic lesions. It is worth notic-
ing that injectable vaccines need the co-administration 
of adjuvants to enhance the preferred immune response 
to weak antigens. In this sophisticated field of vaccine 
improvement, LAB have attracted much interest for anti-
gen delivery, since they have proved to have intrinsic adju-
vant characteristics through inducing and upregulating the 
expression of some cytokines such as IL-12 and IL-10 
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after consumption, resulting in stimulation and activation 
of immature human bone marrow dendritic cells [47, 48]. 
Altogether, it is logical to postulate that attention should 
be focused toward generating new generation of thera-
peutic HPV vaccine. To address these shortcomings, in 
recent years, the next generations of HPV vaccines includ-
ing LAB-based HPV vaccines have been developed and 
reached the clinical trial studies. Their results indicated 
that this type of vaccines can elicit both potent humoral 
and mucosal immune responses against E6 and E7 trans-
forming proteins [49–53]. Data from preclinical studies 
[20, 35] supported the results of phase I clinical trials of 
Iranian researchers and reported that L. lactis vaccines 
could produce HPV-16 specific serum-IgG and vaginal-
IgA antibodies, along with CTL response in PBMCs and 
vaginal discharge of sexually active healthy females. 
Also, long-term E6- and E7-specific CTL responses were 
obtained during the 6-month follow-up period in the same 
participants [49, 50]. Furthermore, the efficacy and safety 
of L. casei vaccine harboring a modified HPV-16 E7 anti-
gen in patients with CIN 3 was evaluated by Kawana et al. 
through phase I/IIa clinical trial. They showed that oral 
consumption of recombinant L. casei in patients suffer-
ing from CIN3 can increase E7-specific cell-mediated 
immune responses in cervical lymphocytes [51]. Also, 
previous data, supporting the data published by Kawana 
et al., revealed that L. lactis vaccine, as for L. casei, can 
induce a systemic cell-mediated immunity which is weaker 
than mucosal cell-mediated immunity in the cervix and 
at mucosal inductive sites [49, 50]. In agreement with 
reports by Iranian scientists regarding prophylactic and 
therapeutic role of recombinant L. lactis to fight against 
HPV-16, Korean researchers emphasized that oral immu-
nization with L. casei vaccine harboring a modified HPV-
16 E7 antigen (BLS-M07) can induce protective humoral 
immune responses via generating HPV-16 E7-specific IgG 
plasma antibody [52]. However, one of the most important 
limitations of this study was that they did not describe 
the precise mechanism of their vaccine for induction sys-
temic and intestinal mucosa immunity. While, previous 
studies displayed that following stimulation of specific B 
cells, APCs can present E7 protein to lymphoid tissues 
of mucosal surface [54, 55]. Also, they stated that CTL 
response was observed in cervical lesions of patients 
who were treated with their vaccine, indicating the posi-
tive connection between CTL response and cure rate. For 
the first time, Bioleader company introduced BLS-M07 
vaccine as a first-in-class orally administered drug which 
employed protein displaying technology  (MucoMax®) for 
treatment of cervical intraepithelial neoplasia. As such, a 
human clinical trial study using L. casei carrying HPV-
16 E7 vaccine on HPV positive patients suffering from 
CIN3 is currently in progress to assess both its safety and 
efficacy. They expected that intermediate results of phase 
3 will be presented by 2021 and the total evaluation of 
study will end in 2022.
Antigen localization influences 
the effectiveness of LAB‑based HPV vaccines
Several studies have described that the cellular location 
of an antigen in a bacterial vector (i.e., intracellular, 
secreted and/or cell-wall-anchored) may affect the sys-
temic and mucosal immune response. Cho et al. identified 
that mucosal immune responses were only stimulated in 
an intracellular production of HPV-16 L1 in the L. lac-
tis MG1363 [25]. In contrast, a group of scientists pro-
duced HPV-16 E7 in both cytoplasm and the extracellular 
forms in L. lactis. They found that extracellular expression 
has higher yields than cytoplasmic expression [56]. Few 
studies have examined the recombinant protein expres-
sion of HPV E6 and E7 antigens by L. lactis in differ-
ent cellular locations. They suggested that if the antigen 
of interest is expressed in either an extracellular or cell 
wall-anchored form, they could have higher expression 
yields than the cytoplasmic protein form, thereby affect-
ing the systemic and vaginal immune responses [57–59]. 
To express a recombinant antigen as a cell-wall-anchored 
and/or secretory form, the protein will be first produced 
as a precursor form in the cytoplasm with a signal pep-
tide (SP), after which this precursor will be exported and 
translocated to the culture supernatants via a cleavage of 
the SP [58]. Thus, to secrete a protein and optimize the 
proteins’ secretion efficiency, a SP should be fused to the 
protein. Until now, for extracellular expression of proteins 
in L. lactis, several efficient SP such as  SPusp45,  SPslpA, and 
 SPprtP have been used. The results of researchers intro-
duced  SPusp45 as the most extensively SP for secretion 
and functional production of HPV-16 E6 and E7 onco-
proteins in L. lactis. This is because of the presence of 
the  SPusp45 the recombinant transcripts can form a stable 
mRNA structure [58, 59]. Accordingly, some research-
ers have tried to produce extracellular forms of HPV-16 
E6/E7 oncoproteins using the  SPusp45 signal peptide [18, 
57–60]. On the other hand, strong evidence suggests that 
the cell wall-anchored form of recombinant E6 and/or E7 
proteins can play a crucial role in enhancing proteins’ sus-
ceptibility to degradation or denaturation agents. It can 
also induce more effective immune response due to adju-
vants’ properties of bacterial cells [35, 61]. The results 
of some studies proved that immunization with L. lactis 
harboring a cell-wall anchor form of E7 antigen induced a 
high level (approximately two-fold higher than other form) 
of E7-specific CTL immune response. These promising 
results were a significant step towards developing a novel 
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and safe mucosal vaccine for treatment of CxCa. So far, 
two important strategies have been developed to produce 
cell-wall anchored HPV antigens, including the use of 
either a cell-wall anchor of the Streptococcus pyogenes M6 
protein (CWAM6) or poly-c-glutamic acid (c-PGA) syn-
thetase complex A (PgsA) from Bacillus subtilis. Cortes-
Perez and colleagues explained a streamlined cell-surface 
display of HPV-16 mutant E7 in L. lactis and Lactobacil-
lus plantarum using  SPusp45 and the cell-wall anchor of 
CWAM6 protein [62].
Growing evidence confirmed that one of the most attrac-
tive expression systems, when using LAB as live delivery 
vehicles, to deliver antigens at mucosal surfaces is the 
Nisin-Controlled gene Expression system (NICE system) 
in L. lactis. Activation of NisR following binding of nisin 
to the receptor NisK resulted in stimulation of the nisin 
operon. For this, nisK and nisR genes are then inserted into 
the chromosome of L. lactis and/or provide in plasmids. To 
this end, cloning of desired genes downstream of this pro-
moter and subsequently adding the sub-toxic amounts of 
nisin results in a tightly-controlled regulation of the other-
wise closed promoter and gene expression. As discussed in 
detail below, researchers using NICE system to express E7 
protein at the cell surface of L. lactis success subsequently 
stimulated HPV-16 E7-specific immune response after 
intranasal administration of their construct in mice [63]. 
Consistent with these findings, another study demonstrated 
that intranasal immunization of mice with recombinant L. 
lactis carrying the cell-wall-anchored form of E7 protein 
induce the production of IL-2 and IFN-γ cytokines from 
splenocytes restimulated in vitro with an HPV-16 E7-spe-
cific CTL epitope [57]. Also, cell surface expression of 
HPV-16 E2 antigen has been successfully achieved in L. 
lactis using  SPusp45 and the cell-wall anchor of CWAM6 
protein [64]. Nevertheless, some results suggested that 
CWAM6 has serious limitations such as concerns about 
the safety for clinical use and less stability than PgsA-
anchored protein. Subsequently, surface display of HPV-
16 E7 in L. casei using a unique PgsA display system 
along with antitumor effects in mice was established by 
Poo et al. They proved that oral consumption of mice via 
the mentioned strain could provoke E7-specific serum IgG 
and mucosal IgA. They also observed that the mice treated 
via L. casei-PgsA-E7 showed diminished tumor size and 
increased survival rate. Finally, their data explained that 
PgsA display system can be used for producing heterolo-
gous proteins with different molecular weights on Gram-
positive bacteria surface [37]. Yoon et al. used a pgsA 
surface display system to show the HPV-16 L2 antigen on 
the surface of L. casei cells. They proved the stimulation 
of L2-specific serum IgG and mucosal IgA in mice receiv-
ing recombinant construct [30]. Also, Lee et al. reported 
the oral immunization of the L. casei-PgsAE6 to mice and 
production of E6-specific cell-mediated immunity [36].
Administration route of LAB‑based vaccine 
and its impact on the stimulation of mucosal 
immunity
Another important aspect for identifying a drug delivery 
system and stimulating immune responses is the admin-
istration routes. The results showed that intramuscular or 
subcutaneous vaccination schemes can only enhance the sys-
temic cellular immunity not local mucosal immunity [32, 
54]. Recently, scientists proved that changing the therapy 
from injection to mucosal immunization can have incredible 
impacts on the vaccine efficacy and proposed numerous ben-
efits over other methods. In this regard, mucosal administra-
tion of antigens is one of the best choices for stimulation of 
mucosal as well as systematic humoral and cellular immu-
nity against pathogens [65]. Accordingly, the outcomes of 
preclinical and clinical studies of LAB-based HPV vaccine 
have postulated that LAB are the best attractive vehicles for 
mucosal vaccination aims. Intranasal, intravaginal, and oral 
routes are the most common routes for mucosal delivery of 
antigens, while oral route is the most fascinating method for 
stimulation of mucosal immunity through mucosal vaccina-
tion. Several studies support the hypothesis that oral admin-
istration of HPV-16 oncoproteins produced by recombinant 
either L. lactis or L. casei to the gut mucosa is the most 
promising therapeutic approach, compared to other routes, 
to elicit an efficient mucosal, humoral, and cellular immune 
response [66]. Most important, in all clinical trials, research-
ers used only oral immunization to deliver the antigen to 
mucus for stimulation of mucosal immunity. Remarkably, 
oral immunization has some advantages over other mucosal 
routes of delivery, including convenience, high safety, cost-
effectiveness, easy self-administration at home, reduction 
in hypersensitivity reactions, and stimulation of either local 
and systemic immune responses [12, 67, 68].
Improving the recombinant expression 
of HPV‑16 antigens and optimization 
of immunization protocols may increase 
the efficacy of therapeutic LAB‑based 
vaccines
According to studies, the antitumor effect of LAB follow-
ing improvement of the expression level of E6/E7 in the L. 
lactis and L. casei, can result in enhanced mucosal immuno-
genicity against HPV. These results emphasized that codon 
optimized E6/E7 oncogenes could efficiently stimulate the 
mucosal and humoral immune responses and can have better 
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inhibitory and treatment effects on tumor growth, which will 
translate into a better survival rate [16, 69].
Considering that culture optimization is an efficient 
approach to promote the overall yield of recombinant pro-
teins, advanced optimization procedures of recombinant 
protein expression including nisin content, induction tem-
perature, cell density at induction time, as well as glucose 
and yeast extract concentrations can result in high lev-
els of E6/E7 expression in the LAB. The results showed 
that the optimal concentration of nisin can lead to peaked 
expression of recombinant E6/E7 in the L. lactis, provid-
ing a dose–response association between E6/E7 synthesis 
and concentration of nisin under optimized environments. 
Surprisingly, according to published data, diminished deg-
radation of the recombinant protein is due to declined tem-
perature of induction [35, 70]. On the other side, from an 
industrial perspective, some results have suggested that large 
batch-to-batch alterations could happen, while production 
of recombinant protein in a fermenter under controlled pH 
conditions will be permitted to regulate significant growth 
factors including pH, temperature, and nutrient supply [59, 
71]. This results in enhanced productivity of the culture 
and expression of E6/E7 protein and biomass, at a high 
efficiency. As reported by some studies, nitrogen source 
can significantly affect the expression of E6/E7 proteins, 
while carbon source can mainly encourage the production 
of biomass [58, 59]. Taken together, the results revealed that 
fermenter experiments in comparison to static flask experi-
ments enhanced the yield of production of E6/E7 oncogenes 
at L. lactis along biomass levels, resulting in substantial spe-
cific serum IgG and vaginal IgA antibodies responses after 
immunization. It is followed by higher production of HPV-
16 E6/E7 specific IFN-γ-secreting T cells and IL-2 [58, 59]. 
These encouraging results suggest efficient application of 
L. lactis as a cell factory for antigen production, showing a 
step towards fast tracking a vaccine against HPV-16-induced 
CxCa.
Elsewhere, some studies indicated that a number of opti-
mization procedures such as application of optimal immu-
nization dose, immunotherapeutic adjuvant, and/or codon 
usage optimization could improve the efficiency of specific 
mucosal immune response and antitumor activity. In this 
regard, consistent with dose-escalation studies and observa-
tion of a dose-dependent response in the groups receiving 
vaccines, some researchers recommended that in the GALT, 
the most important factor for stimulating antigen-presenting 
cells is optimizing the vaccine dose [72]. Accordingly, it 
was found that the inductive efficiency of specific mucosal 
immune response in animals and humans was associated 
with the number of viable colonies of LAB (colony-form-
ing units: CFU) harboring E6/E7 antigens [54]. In another 
study, γ-PGA was introduced as a potent immunotherapeutic 
adjuvant for better induction of antitumor activity of oral L. 
casei-E7-based vaccine against cervical cancer [6]. Similar 
to the previous study, Rangel-Colmenero et al. reported bet-
ter tumor suppression effect of intranasal pre-vaccination 
with recombinant L. lactis harboring E7 in combination 
with Adenovirus expressing calreticulin-E7 (Ad-CRT-E7) 
as compared to applying the mentioned vaccine alone [73]. 
Based on the recommendation of literature, codon usage 
optimization was reported as another important aspect of 
vaccine development and can successfully be used to dra-
matically improve the expression of E6/E7 oncoproteins in 
the L. lactis [16, 69].
Are LAB‑based vaccines safe for elimination 
and treatment of CxCa associated HPV?
Safety of live recombinant vaccine for use in human is an 
important concern which can be discussed in three aspects, 
including type of microbial delivery antigen, physiology 
of host affected by heterologous genes, and transferring of 
antibiotic resistance gene. Data have shown a wide range 
of adverse effects in vaccination with Salmonella and Lis-
teria, compared to vaccination with lactic acid bacteria 
against HPV, suggesting vaccination with LAB as a good 
and promising alternative approach than traditional attenu-
ated pathogenic bacterial vaccine [49, 74, 75]. LABs are 
generally recognized as safe (GRAS), and do not possess 
endotoxic lipopolysaccharides or other toxic substances, 
and have traditional effect on human health [76]. Likewise, 
pre-clinicals and clinical trials have shown that delivery of 
antigens by LAB via intranasal and oral routes in contrast 
to other delivery vehicles of HPV antigens does not cause 
significant side effects [77–79]. Regarding the oncogenic 
status of HPV antigens and possibility for dissemination of 
foreign genes to other bacteria in the gut, some studies have 
reported diminished transforming activity of HPV onco-
genes via mutation in HPV-16 E7 gene, causing elimination 
of its oncogenicity but not its immunogenicity. Although 
mutations of amino acid derived from the oncogenic struc-
tures of HPV-16 E6 and E7 should be well considered, since 
any changes in the transforming gene E6/E7 may cause dif-
ferent biological functions and may influence the induction 
of immune response [18, 80]. Also, the usage of genetically 
modified microorganisms increases legitimate worries about 
dissemination of antibiotic selection markers in the environ-
ment or propagation and transference of genetic modifica-
tion to other microorganisms. Thus, biologic containment 
of recombinant bacteria is necessary before administering 
live vaccines to humans [81]. Another strategy discussed 
in some studies is application of heat-attenuated LAB to 
prevent the transference of antibiotic-resistance genes in the 
delivery of antigen to animal models and humans, resulting 
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in the degradation of the shuttle plasmid and inhibition of 
self-replication [32, 51].
Conclusion
As discussed herein, gut-vagina axis is one of the most 
promising steps towards advanced prophylactically as well 
as therapeutically approaches to treat CxCa. Despite inten-
sive efforts by many groups over the past 20 years, surpris-
ingly little is known about how the modulation of gut micro-
biota via mucosal LAB-based vaccine and its derived signals 
to the vagina protects the female genital tract against HPV. 
Although we are aware about the modulatory effect of LAB-
based vaccine on HPV in CxCa, much detail remains to be 
clarified. Of note, some studies indicate that active immune 
deviation to E6/E7 CMI responses has almost certainly 
developed in most patients with advanced HPV-induced 
lesions. However, we did not find any evidence concerning 
LAB-based vaccines that overcome these suppressive effects 
relative to other vaccination strategies.
It is thought that improvement in mucosal delivery and 
immunomodulation technology when using LAB vectors 
can open an avenue for the development of novel future 
oral vaccines against HPV. Definitely, the understanding 
of gut-vagina axis involvement in the efficacy of LAB-
based vaccines in a large cohort of patients with CxCa and 
its inter-organ influences should not be disregarded. This 
knowledge gap and a one-solution-fits-all approach denotes 
a major challenge to the development of proof-of-concept 
clinical trial for elucidating and ascertain the exact causa-
tive mechanisms linking LAB-based vaccines and HPV, in 
particular CxCa. Overall, the data presented in this review 
showed a starting point for better clarification of the mech-
anism involved in gut and vagina communication for the 
stimulation of mucosal immune response. This can result 
in development of an effective preparation for expansion 
of therapeutic vaccines against cervical cancer. In summa-
tion, future investigation of this area is likely to yield fruit-
ful results and this delicate and sophisticated approach will 
hopefully bridge the gap between association and causation.
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